Bausch Health Lubricates Bausch + Lomb's Pending Separation With Hydration Eye Drops Launch
Biotrue Hydration Boost contains glyercrin, available in the US as an ophthalmic remedy under an FDA OTC monograph. Launch is latest addition to Baush + Lomb consumer portfolio as Bausch Health prepares to make it a standalone firm.
You may also be interested in...
Bausch + Lomb IPO Will Open Tap Further For Paying Down Bausch Health Debt
Paying down Bausch Health’s debt, incurred during previous management’s expansion-by-acquisition strategy when the firm operated as Valeant, has been a box to check from the start of preparing to separate Bausch + Lomb, says CEO Joseph Papa.
Bausch + Lomb Second On Bausch Health IPO Card
Canadian firm plans to separate Solta first, with an IPO in December or January, and at least 30 days later offer shares in Bausch + Lomb. Order of IPOs could change, though.
Bausch Health Has Full Plate While Trimming Debt, Setting Table For Bausch + Lomb Separation
Bausch Health says it’s continuing a recovery from the disaster previous management left, when the firm operated as Valeant Pharmaceuticals, even though it reported a $595m net loss for Q2. “We've been trying to solve this debt issue for the company,” says CEO Joseph Papa.